---
title: "Rongchang Biologics surges 8% as H1 profit forecast shows turnaround"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295186906.md"
description: "Rongchang Biologics surged 8% to HK$85.95 after H1 profit forecast of 4.7 billion yuan, its first profit since listing."
datetime: "2026-08-07T06:06:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295186906.md)
  - [en](https://longbridge.com/en/news/295186906.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295186906.md)
generator: "portal-rs"
---

# Rongchang Biologics surges 8% as H1 profit forecast shows turnaround

Rongchang Biologics (9995.HK) surged more than **8%** in Hong Kong trading to **HK$85.95**. The company issued a positive profit alert, forecasting first-half 2026 revenue of approximately **5.85 billion yuan**, up more than 4.3 times from a year earlier, and net profit of about **4.7 billion yuan**, marking a turnaround to profitability — the first time the company has achieved scaled earnings since its listing.

The strong performance was driven by continued domestic sales growth of its core products Telitacicept and Disitamab vedotin, as well as the recognition of substantial technology licensing revenue from an exclusive overseas licensing agreement with AbbVie for RC148, a PD-1/VEGF bispecific antibody.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)

## Related News & Research

- [RemeGen files HKEX next-day disclosure return reporting share buyback on Shanghai exchange at RMB 113.43 per share](https://longbridge.com/en/news/298706225.md)
- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [Lingbao Gold to buy remaining 50%-1 stake in Tabar Islands Holdings for AUD 410 million](https://longbridge.com/en/news/298509376.md)
- [Guangzhou Industry Investment joins Blue River Technology’s Series B financing round](https://longbridge.com/en/news/298663636.md)
- [CIF/FOB Gulf Grain-Soybean barge basis steady-weak as futures rally](https://longbridge.com/en/news/298650009.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**